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Abstract. Over- or under-expression of erythropoietin-production human hepatocellular receptors (Eph) and
their ligands are associated with various diseases. Therefore, these molecular biomarkers can potentially be
used as binding targets for the delivery of therapeutic and/or imaging agents to cells characterized by such
irregular expressions. We have engineered nanoparticles derived from erythrocytes and doped with the
near-infrared (NIR) FDA-approved dye, indocyanine green. We refer to these nanoparticles as NIR erythro-
cyte-derived transducers (NETs). We functionalized the NETs with the ligand-binding domain of a particular
Eph receptor, EphB1, to target the genetically modified human dermal microvascular endothelial cells
(hDMVECs) with coexpression of EphB1 receptor and its ligand ephrin-B2. This cell model mimics the patho-
logical phenotypes of lesional endothelial cells (ECs) in port wine stains (PWSs). Our quantitative fluorescence
imaging results demonstrate that such functionalized NETs bind to the ephrin-B2 ligands on these hDMVECs in
a dose-dependent manner that varies sigmoidally with the number density of the particles. These nanoparticles
may potentially serve as agents to target PWS lesional ECs and other diseases characterized with over-expres-
sion of Eph receptors or their associated ligands to mediate phototherapy. © The Authors. Published by SPIE under a Creative
Commons Attribution 4.0 Unported License. Distribution or reproduction of this work in whole or in part requires full attribution of the original publication,
including its DOI. [DOI: 10.1117/1.JBO.24.8.085002]
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1 Introduction
Erythropoietin-production human hepatocellular (Eph) recep-
tors are the most abundant subgroup of receptor tyrosine kin-
ases, with at least 16 different members being expressed in
humans.1 These receptors are divided into two subclasses based
largely on their binding affinities for the two subclasses of eph-
rin ligands (ephrin-A or ephrin-B), and are referred to as EphA
or EphB receptors.1–5 EphA receptors tend to bind ephrin-A
ligands; while EphB receptors preferentially bind to ephrin-B
ligands.1–5 These receptors and ligands are involved in a number
of physiological processes involving the development of the
nervous system, angiogenesis, and cell migration.3,4,6,7
Over- or under-expression of Eph receptors and their ligands
have been associated with lung, breast, and prostate cancers, as
well as melanomas and leukemia.8 Some Eph receptors and eph-
rins have also been reported to play a role in bone homeostasis
and implicated in myeloma bone disease, osteolytic bone dis-
ease associated with breast cancer metastasis,9 and skeletal
deformities including cleft palates and craniosynostosis.10
Deregulation of Eph receptor and ephrin ligand signaling has
also been implicated in aberrant synaptic functions associated
with neurodegenerative diseases such as Alzheimer’s disease.11
Recently, we found that EphB1 receptors and ephrin-B2 ligands
are coexpressed on the lesional endothelial cells (ECs) in
patients with port wine stains (PWSs).12
Due to their abundance on a variety of cell types, Eph recep-
tors and their ligands have become viable targets for therapeutic
agents that can be conjugated to various targeting moieties
including peptides, antibodies, and the ephrins themselves.13–20
For example, Blevins et al.15 conjugated a peptide that targets
EphA2 and EphA4 to a PEG linker and a polymer for the deliv-
ery of therapeutic plasmids to the pancreas. Targeting the Eph/
ephrin system has also been done by attaching the targeting
agent to a variety of nanoparticles. For example, various target-
ing agents have been conjugated to hollow gold nanospheres,
gold-coated silica nanoshells, biosynthesized magnetite nano-
particles, liposomal nanoparticles, and gold nanorods.14,16–19
In addition to delivering therapeutics, some nanoparticles can
deliver imaging and photodynamic therapy agents to specific
cells.13,14,20
Recently, use of cells such as erythrocytes or nanoparticles
coated with cell membranes as therapeutic or imaging platforms
has drawn increased attention.21–31 A particular feature of eryth-
rocytes that distinguishes them from other cell types is their nat-
urally long circulation time (≈90 to 120 days) attributed to the
presence of “self-marker” proteins on their surface to inhibit the
immune response.32,33 One putative self-marker is CD47 glyco-
protein, which impedes phagocytosis through signaling with
phagocytes receptor, SIRPα.34–37 Hence, constructs derived
from erythrocytes may provide their cargo available in circula-
tion for prolonged times.38 For example, Hu et al. reported that
polymeric nanoconstructs coated with erythrocyte-derived
membranes were retained in mouse blood for 3 days with a cir-
culation half-life of ≈8 h.21 As constructs that can be engineered
autologously (or from similar blood types), erythrocyte-derived
particles also present a potentially nontoxic and biocompatible
delivery platform.
We provided the first report of erythrocyte-derived nanopar-
ticles doped with the FDA-approved near-infrared (NIR) dye,
indocyanine green (ICG).22 We refer to these constructs as
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NIR erythrocyte-derived transducers (NETs) since, once photo-
excited by an appropriate NIR wavelength, ICG can transduce
the absorbed light energy to emit fluorescence, generate heat, or
mediate the production of reactive oxygen species.39 We have
previously demonstrated the effectiveness of antibody-function-
alized NETs in targeted imaging of ovarian cancer cells, as well
as NETs functionalized with tissue plasminogen activator as a
theranostic agent for NIR fluorescence imaging and thrombol-
ysis of blood clots in vitro.23,24
Herein we report for the first time the engineering of NETs
functionalized with the ligand binding domain (LBD) of the
EphB1 receptor (Fig. 1). We chose the LBD of the EphB1 recep-
tor as the targeting agent since it has a strong binding affinity for
the ephrin-B2 ligand.3 We demonstrate the effectiveness of such
functionalized NETs (F-NETs) in targeting ECs that over-
express the ephrin-B2 ligand by fluorescence imaging. These
optical constructs can potentially be useful to target the eph-
rin-B2 ligand on a variety of diseases ranging from cancer cells
to PWS ECs.
2 Materials and Methods
2.1 Fabrication of NETs and F-NETs
Erythrocytes were isolated from either bovine or human whole
blood (Rockland Immunochemicals, Inc. and Innovative
Research, Inc., respectively) via centrifugation (1000 × g for
5 to 10 min at 4°C). The plasma and buffy coat were removed,
and the erythrocyte pellet was resuspended in ≈320 mOsm
phosphate buffered saline (PBS) (defined as 1 × PBS).
Erythrocytes were centrifuged (1000 × g for 5 to 10 min at
4°C) and washed with 1 × PBS three times with the supernatant
discarded after each wash. The erythrocyte pellet was then
subjected to hypotonic treatment by resuspension in 0.25 ×
PBS (≈80 mOsm) for ≈10 min followed by centrifugation
(20;000 × g for 20 min at 4°C). The supernatant containing
hemoglobin was discarded, and the hypotonic treatment was
repeated until the erythrocyte pellet was opaque, indicating the
formation of erythrocyte ghosts (EGs).
To form nonfunctionalized NETs, EGs were extruded
sequentially through 400- and 200-nm polycarbonate porous
membranes (VWR, Inc.) using an Avanti mini extruder (Avanti
Polar Lipids, Inc.), resulting in nano-sized EGs (nEGs). These
nEGs were then suspended in a solution made of equal volumes
of 1 × PBS, 0.1 M Sϕrenson’s buffer (Na2HPO4∕NaH2PO4,
140 mOsm, pH ≈ 8), and ICG solution (Fisher Scientific
Company). Concentration of ICG in the loading buffer solution
was either 25 or 33.33 μM, depending on the experiment. The
solution was then centrifuged (≈56;000 × g for 1 h at 4°C) and
the supernatant was removed. The pellet, comprised of NETs,
was then resuspended in 1 × PBS, centrifuged, and washed two
times. NETs were resuspended in 1 × PBS for experiments.
To fabricate F-NETs, we proceeded as follows. EGs (as pre-
pared above) were centrifuged (20; 000 × g for 15 min at 4°C)
and the supernatant was discarded (Fig. 2). We made a solution
Fig. 1 Schematic of a PWS EC that coexpresses the EphB1 receptor and ephrin-B2 ligand. F-NETs are
functionalized with the LBD of EphB1 to selectively bind to ephrin-B2.
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consisting of 5 mg of a linker, 1,2-distearoyl-sn-glycero-3-phos-
phoethanolamine-polyethylene glycol-aldehyde (DSPE-PEG-
CHO) (2000 Da PEG) (Nanocs, Inc.) dissolved in 1 ml nanopure
water. We added 20 μl of this lipid linker solution to 1 ml of EGs
in nanopore water and let the solution incubate (30 min at room
temperature). The resulting lipid-inserted EGs were then filtered
through 50k Amicon Ultra-4 centrifuge filter units (Millipore)
via centrifugation (≈1700 × g for 10 to 15 min at room temper-
ature) to remove excess linker. As excess lipid-linker and nano-
pore water were removed through the filter units, the lipid-
inserted EGs remained suspended in solution by replenishing
with 1 × PBS. Lipid-inserted EGs were then extruded, and then
loaded with either 25 or 33.33 μM ICG in the loading buffer (as
described above). The resulting NETs with lipid-inserted linker
were resuspended in 1 × PBS and incubated with 10 μg∕ml
recombinant Rat EphB1 Fc Chimera Protein, Cf (R&D
Systems, Inc.) (hereafter referred to as the EphB1 LBD) for
5 min at room temperature in the dark. This chimera protein
is composed of the extracellular LBD of rat EphB1, a short pol-
ypeptide sequence, and human IgG1. We added 5 μl of 20-mM
sodium dithionite, as the reducing agent, to the solution contain-
ing the NETs with lipid-inserted linkers, and incubated for 1 h at
4°C in the dark. The amine group on the C-terminus end of the
EphB1 LBD protein serves as the site for covalent coupling with
the aldehyde group on the end of the lipid linker, induced by
reductive amination reaction. During this reaction, the Schiff
base formed at the site of covalent coupling is reduced by the
sodium dithionite, irreversibly converting the imine to a more
stable amine. This reaction results in covalent attachment of the
EphB1 LBD to NETs. The resulting pellet, comprised of F-
NETs, was then washed in 1 × PBS and centrifuged as described
above before being resuspended in 1 × PBS (Fig. 2).
2.2 Dynamic Light Scattering-Based Measurements
of Particle Diameters
Hydrodynamic diameters of NETs and F-NETs suspended in
1 × PBS were measured by dynamic light scattering (DLS)
(Zetasizer Nanoseries, NanoZS90, Malvern Instruments). All
measurements were made with the particle suspensions in
Fig. 2 Schematic of steps to fabricate F-NETs. (1) EGswere formed by depleting the hemoglobin content
of erythrocytes. (2) EGs were incubated with a DSPE-PEG-CHO linker for insertion into the lipid phase of
EG’s shell. (3) Micron-sized EGs (μEGs) with lipid-inserted linkers were extruded to make linker bearing
nano-sized EGs (nEGs). A zoomed-in cross-section of the extruder filters with nano-sized pores for extru-
sion of μEGs into nEGs is shown. (4) nEGs with lipid-inserted linkers were loaded with ICG in a hypotonic
solution resulting in formation of nano-sized NETs containing lipid-inserted linkers. (5) The EphB1 LBD
was covalently attached to the terminal end of lipid-inserted linkers using a reductive amination reaction
to functionalize the NETs. For illustration purposes, we also show one of the erythrocyte membrane
proteins, CD47.
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polystyrene cuvettes with a 1-cm pathlength. Measurements
were collected three times for each sample and averaged to cal-
culate the mean diameter and standard deviation (SD) for each
population sample. The percentage of each sample’s population
associated with a given diameter was plotted, and data were fit
with a Lognormal function using Igor.
2.3 Absorption and Fluorescence Spectra of NETs
and F-NETs
Absorption spectra of NETs and F-NETs suspended in 1 × PBS
were recorded in the 280- to 1000-nm spectral range using a UV
visible spectrophotometer (Cary 50 UV-Vis spectrophotometer,
Agilent Technologies) with an optical path length of 1 cm. Both
NETs and F-NETs were fabricated using 25 μM ICG in the
loading buffer. Suspensions of NETs or F-NETs, diluted to have
absorbance values of one at 800 nm, were designated to have the
relative number density (N) of 1× when suspended in 1 × PBS.
To obtain solutions with a lower N, the nanoparticle solutions
were diluted by increasing the volume of 1 × PBS as desired. To
obtain solutions with a higher N, the nanoparticle solutions
were concentrated using less 1 × PBS as desired. We prepared
solutions of NETs and F-NETs with N ranging from
0.25× (lowest relative number density of nanoparticles) to 2×
(highest relative number density of nanoparticles) for various
experiments.
Fluorescence spectra of NETs and F-Nets suspended in 1 ×
PBS in response to photoexcitation at 720 2.5 nm with a 450-
W xenon lamp were acquired using a fluorometer (Fluorolog-3
spectrofluorometer, Edison). We normalized the wavelength (λ)-
dependent fluorescence emission χðλÞ as follows:
EQ-TARGET;temp:intralink-;e001;63;414χðλÞ ¼ FðλÞ
1 − 10−AðλexÞ
; (1)
where F is the fluorescence emission intensity in response to
photo-excitation at a given λ, and AðλexÞ is the absorbance of
the sample at the excitation wavelength. For this characteriza-
tion, both sets of NETs and F-NETs were fabricated using
33.33 μM ICG in the loading buffer.
2.4 Functionalization Validation
We validated the functionalization of NETs with the LBD of
the EphB1 receptor by using immunofluorescent staining.
Specifically, NETs (control) and F-NETs were fabricated using
33.33 μM ICG in the loading buffer and incubated with 10 μl
human IgG Fc Phycoerythrin (PE)-conjugated antibodies (R&D
Systems, Inc.) per 1 ml of NETs or F-NETs solution for 1 h at
room temperature in the dark. These antibodies bind to the
human IgG1 portion of the EphB1 LBD. Nanoparticles were
centrifuged and washed in 1× PBS three times and then photo-
excited at 488 2.5 nm (450-W xenon lamp) to elicit emission
from the PE. The resulting fluorescence emission spectra were
recorded and normalized as described above.
2.5 Human Dermal Microvascular Endothelial Cell
Culture and Transfection
Human dermal microvascular endothelial cells (hDMVECs)
were cultured in endothelial cell basal medium (ECBM) with
growth supplement (Cell Applications, Inc.) as previously
described.12 In order to establish the EC models with
coexpression of EphB1 receptors and ephrin-B2 ligands, which
mimic the pathological phenotypes of PWS ECs, we isolated a
subset of normal hDMVECs with high expression of surface
EphB1 receptors via biotinylated chimera ephrin-B2-Fc, which
contains the extracellular portion of ephrin-B2 ligands and is
capable of binding to EphB1 receptors, and streptavidin-conju-
gated magnetic beads. The rationale of this selection is that
the ephrin-B2-Fc chimera ligand binds to EphB1þ∕EphB4þ
expressing venous and capillary hDMVEC subpopulation,
while the remaining arterial hDMVEC subpopulation
(EphB1−∕EphB4−) express ephrin-B2 ligands.
Specifically, 100 μg of the streptavidin-conjugated magnetic
beads were incubated with 2 μg of biotinylated chimera ephrin-
B2 Fc at room temperature for 15 min before the ephrin-B2
Fc-magnetic bead complex was removed from solution via
magnetic strands. The bead complex was then incubated with
≈5 × 105 hDMVECs on ice for 30 min. The cells that bound
to the bead complex were isolated and designated as
EphB1þ∕ephrin-B2− hDMVECs, which have previously been
verified to express the EphB1 receptor, with undetectable eph-
rin-B2 levels.12
Lentiviral vector pLX304-EphrinB2 containing human
ephrin-B2 cDNA was obtained from DNASU (Clone ID:
HsCD00446022). Control lentiviral vector pLIM1-EGFP
(enhanced green fluorescent protein) was obtained from
Addgene (Plasmid ID: 19319). The third-generation lentiviral
packaging plasmids were used to produce pLX304-EphrinB2
and pLIM1-EGFP lentiviruses in Phoenix cells. The ephrin-
B2 selected hDMVEC subpopulation showed a higher level
of EphB1 mRNA and a much lower level of ephrin-B2
mRNA as compared to nonselected heterogeneous hDMVEC
populations.12 EphB1þ∕ephrin-B2− hDMVECs were infected
by either lentiviruses containing EGFP ðEGFPþ∕EphB1þ∕
ephrin-B2− hDMVECs) (referred to as control cells) or human
EphrinB2 cDNA to overexpress ephrin-B2 (EphB1þ∕
ephrin-B2þ hDMVECs) (referred to as ephrin-B2 cells). The
cells were continuously cultured for 2 weeks to allow the expres-
sion of transgenes for the F-NETs experiments. The ephrin-B2
expression in the hDMVECs was determined by Western blot
assay, as we previously described. Beta-actin was used as the
internal loading control.12
2.6 Targeting Ephrin-B2 Ligands by F-NETs
To determine the effectiveness of the F-NETs to target the eph-
rin-B2 ligand, we incubated the control and ephrin-B2 cells with
either NETs or F-NETs for 40 min at 4°C in the dark. The incu-
bating solution consisted of 50% human ECBM containing 10%
fetal bovine serum (FBS) by volume, with the nanoparticles in
1 × PBS forming the other 50%. Both NETs and F-NETs were
fabricated using 33.33 μM ICG in the loading buffer solution.
The relative number density of the particles (ρ) in 1 × PBS and
ECBM with 10% FBS cell media was defined as
EQ-TARGET;temp:intralink-;e002;326;173ρ ¼ N
 Vnanoparticles
Vnanoparticles þ VECMB
; (2)
where Vnanoparticle is the volume of NETs or F-NETs suspension
in 1 × PBS, and VECBM is the volume of ECBM and 10% FBS.
Cells were incubated with NETs having ρ of 0.5×, and F-NETs
with ρ values ranging from 0.03× to 0.5×.
After incubation, cells were stained with 500 μl of 4’,6-dia-
midino-2-phenylindole (DAPI) (10 to 11 μM) for subsequent
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fluorescence microscopy imaging experiments. DAPI fluores-
cence emission in response to photo-emission at 360 20 nm
by a xenon/mercury arc lamp (Nikon Eclipse Ti-S microscope
with an Osram Sylvania XBO75W/2 bulb, Interlight) was cap-
tured by an electron multiplier gained CCD camera (Quant EM-
CCD, C9100-14 Hamamatsu) over the spectral band of 435 to
485 nm. NIR fluorescence emission (>770 nm), emanating
from ICG in NETs, was captured in response to photoexcitation
at 740 35 nm. We present falsely colored fluorescent images
associated with DAPI-stained nuclei (blue channel) and ICG
emission (red channel).
2.7 Image Analysis
Acquired NIR fluorescent images of the cells were analyzed
using ImageJ software. Regions of interests (ROIs) were
selected on a given image. The mean intensity I value from
a given set of ROIs was calculated as
EQ-TARGET;temp:intralink-;e003;63;557I ¼
P
m
l¼1
P
n
k¼1
P
p
j¼1 I
ROI
j −I
Background
j
p

m  n ; (3)
where IROIj is the fluorescence emission intensity at the j’th pixel
in the ROI of a given image, Ibackgroundj is the fluorescence emis-
sion intensity corresponding to the background region of the
same image, p is the total number of pixels in a given ROI,
n is the number of ROIs, and m is the number of images
obtained from the cell population. Multiple ROIs were selected
from a given image, and multiple images from a cell population
were used to calculate I for each population of cells.
3 Results and Discussion
3.1 Hydrodynamic Diameter Distribution of NETs
and F-NETs
As determined by fitting lognormal distributions to DLS-based
measurements, the average hydrodynamic diameters SD of
nonfunctionalized NETs and F-NETs were 127.96 1.58 and
156.76 2.52 nm, respectively (Fig. 3). Our previously pub-
lished transmission electron and scanning electron microscopic
images of NETs have shown that DLS-based measurements of
NETs diameter are consistent with those obtained by electron
microscopy.22,23 The increase in the mean diameter of
F-NETs by ≈28.8 nm suggests that the thickness of the linker
and the LBD coated onto the F-NETs was ≈14.4 nm. Minelli
and Shard40 measured the thickness of 2-kDa thiol terminated
methoxy PEG coatings on gold nanoparticles to range from
≈3 to 16 nm. The DPSE-PEG-CHO linker used in our function-
alization of NETs has a similar structure to the linker used by
Minelli and Shard. Therefore, our estimate of the coating thick-
ness is reasonable and consistent with this previous literature.
3.2 Absorption and Fluorescence Spectra of NETs
and F-NETs
Absorption spectra of NETs and F-NETs suspensions in
1 × PBS as a function of N of the particles are shown in
Figs. 4(a) and 4(b), respectively. Absorption at ≈795 and
≈735 nm corresponds to the monomeric and H-like aggregate
forms of ICG, respectively.22,41,42 There was a near linear rela-
tionship between the absorbance values at 795 nm and N. For
example, when N was increased to 2×, the absorbance value at
795 nm increased from ≈1.0 to ≈1.8 for both sets of nanopar-
ticles. The similar absorbance values at 795 nm for NETs and F-
NETs for all N values suggests that the loading efficiency of
ICG was the same for both sets of nanoparticles.
There was a similar near-linear relationship between the
absorbance values at 280 nm, the wavelength associated with
the protein absorption43 of NETs, and N. For example, when
N was increased to 2×, the absorbance value at 280 nm
increased from ≈0.8 to ≈1.4 for both sets of nanoparticles.
For the same N, there were minimal differences between the
absorbance values at 280 nm for NETs and F-NETs. This result
suggests that for a given N, the population of F-NETs and
NETs had the same amount of proteins, and the EphB1 LBD
did not contribute to the absorbance of F-NETs at 280 nm.
In response to photoexcitation at 720 2.5 nm, NETs and F-
NETs produced nearly identical fluorescence emission spectra
in the 735- to 900-nm band [Fig. 5(a)], associated with the
monomer form of ICG.42 Successful functionalization of
NETs with the EphB1 LBD was evidenced by the drastically
different fluorescence emission spectrum of F-NETs over the
550- to 630-nm spectral band, in response to 488 2.5 nm pho-
toexcitation, as compared to that of the NETs [Fig. 5(b)]. This
band is associated with the fluorescence emission of the phyco-
erythrin (PE) dye44,45 that was conjugated to the antibodies that
bind to the human IgG1 part of the EphB1 LBD. The emission
spectra provide evidence toward successful functionalization of
the F-NETs with the EphB1 LBD [Fig. 5(b)], while at the same
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Fig. 3 Hydrodynamic diameters of NETs and F-NETs suspensions.
Suspensions were in PBS and the hydrodynamic diameters were
measured by DLS. We present the average (circles) with SD values
(error bars) associated with three measurements of a sample.
Lognormal distributions are fitted to the measured data (solid traces).
Black data points and traces correspond to the NETs population,
while the red data points and traces correspond to the F-NETs
population.
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Fig. 4 Absorption spectra of NETs and F-NETs. Absorption spectra
of: (a) NETs and (b) F-NETs recorded in 1 × PBS for various values of
N ranging between 0.25 and 2×. Both NETs and F-NETs were fab-
ricated using 25 μM ICG in the loading buffer.
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time demonstrating that the NIR emission characteristics of
F-NETs remained unaltered as compared to that of NETs
[Fig. 5(a)].
3.3 Targeting Ephrin-B2 Ligands by F-NETs
We verified the expression of ephrin-B2 on hDMVECs using a
Western blot (Fig. 6). Even when incubated with NETs at the
highest ρ value (0.5×), there was minimal NIR fluorescence
emission from the control and ephrin-B2 hDMVECs (image not
shown), suggesting that nonfunctionalized NETs were not effec-
tively uptaken by either cell type. We quantified the average NIR
emission (I) using Eq. (3). There were no statistically significant
differences among I values for control hDMVECs whether incu-
bated with NETs or F-NETs with ρ value of 0.5× (data not
shown), suggesting that both particles were uptaken at about the
same levels by the control hDMVECs. These results further sug-
gest that the interaction of control hDMVECs with either NETs
or F-NETs is likely due to nonspecific binding, with uptake of
the particles by clathrin-mediated endocytosis or caveolae-de-
pendent endocytosis.46
There was also minimal NIR fluorescence emission from
control hDMVECs after incubation with F-NETs, regardless
of the ρ value investigated (images not shown). This result
suggests that F-NETs were not effective in targeting
hDMVECs that lacked the ephrin-B2 ligand. NIR emission
from the ephrin-B2 hDMVECs emerged when the ρ value for
F-NETs exceeded 0.12×, suggesting that there was a threshold
number density of F-NETs for effective targeted imaging of
ephrin-B2 hDMVECs [Fig. 7(a)].
As the ρ value of F-NETs increased from 0.03× to
0.5×, there was no clear trend in I values for control
hDMVECs [Fig. 7(b)]. There were also no statistically signifi-
cant differences in I values associated with control and ephrin-
B2 hDMVECs when the ρ value of F-NETs was 0.03× or
0.06×. However, for ρ ≥ 0.12× there were statistically signifi-
cant differences (p < 0.001) between the I values associated
with the control and ephrin-B2 hDMVECs. Specifically, for
ephrin-B2 cells, there was a sigmoidal relationship between the
I values and ρ value of F-NETs [Fig. 7(c)]. This result suggests
that a threshold number density of F-NETs (ρ ¼ 0.12×) was
needed to overcome nonspecific binding between F-NETs and
ephrin-B2 hDMVECs. Once those nonspecific binding sites
were saturated, excessive F-NETs occupied almost all the
available specific EphB1 LBD positions on the ephrin-B2
hDMVECs.
A particular application of F-NETs relates to laser treatment
of cutaneous capillary malformations, PWSs. PWSs are cur-
rently treated by laser irradiation using visible wavelengths in
the range of 585 to 595 nm. These wavelengths target the endog-
enous hemoglobin to induce photothermal destruction of the
PWS vasculatures.47 However, the melanin pigment within the
melanocytes, located in the basal epidermal layer of skin and
residing over the abnormal plexus of dermal blood vessels, has
relatively strong optical absorption over the current laser treat-
ment band. For example, at treatment wavelength of 585 nm, the
absorption coefficient of a melanosome is comparable to that of
oxyhemoglobin.48 As such, the photons intended to reach the
dermal vasculature would be partially absorbed within the epi-
dermis. The outcome is nonspecific thermal injury to the epider-
mis and insufficient heat generation within the vasculatures,
leading to an inadequate treatment.
An alternative phototherapeutic approach can potentially be
developed by using NIR wavelengths in conjunction with intra-
vascular administration of F-NETs. For example, by changing
the treatment wavelength from 585 to 755 nm, nearly threefold
reduction in the absorption coefficient of a single melanosome
can be achieved.48 This approach offers several advantages:
(1) reduced risk of nonspecific thermal injury to the epidermis
to potentially allow treatment of individuals with moderate to
heavy pigmentation;49 (2) increased depth of optical penetration
to reach deeply seated blood vessels (e.g., >500 μm below the
skin surface);49 (3) targeted delivery of F-NETs to the ECs
within the PWS vasculature where the ephrin-B2 ligand is
over-expressed;12 and (4) heat generation within the blood ves-
sels resulting from the absorption of ICG within the F-NETs to
induce photothermal destruction of the lesional vasculature
plexus.
4 Conclusions
To the best of our knowledge, we have demonstrated for the
first time the fabrication of erythrocyte-derived nanoparticles
containing ICG, and functionalized with the EphB1 LBD to
target cells that express ephrin-B2. Optical absorption and
fluorescence characteristics of NETs remain unaltered upon
functionalization with EphB1 LBD. Our quantitative imaging
(a) (b)
Fig. 5 Normalized fluorescence emission spectra of NETs and F-
NETs. (a) Normalized fluorescence emission spectra of NETs and
F-NETs in response to photo-excitation at 720 2.5 nm. We present
the average (circles) with SD values (error bars) associated with four
samples. Gaussian functions fit the data (solid traces). (b) Normalized
fluorescence emission spectra of non-functionalized NETs and F-
NETs after incubation with human PE-labeled IgG Fc antibodies in
response to photoexcitation at 488 2.5 nm. All spectral recordings
were made with the particles suspended in 1 × PBS and N ¼ 1×.
Both NETs and F-NETs were fabricated with 33.33 μM ICG in the
loading buffer.
ephrin-B2 lentivirus
ephrin-B2
actin
Fig. 6 Ephrin-B2 Western blot expression. Western blot showing the
expression of ephrin-B2 in hDMVECs infected with an ephrin-B2 len-
tivirus compared to the ephrin-B2 expression level of hDMVECs not
infected with the ephrin-B2 lentivirus. Beta-actin levels are shown as
the internal loading control.
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fluorescence imaging results suggest that the uptake of such
functionalized NETs by ephrin-B2 expressing cells follows a
sigmoidal function that depends on the relative number density
of F-NETs in the incubating medium.
Disclosures
The authors do not have any conflicts of interest to declare.
Acknowledgments
This study was supported in parts by grants from the National
Science Foundation (CBET-1509218 to B.A.) and the National
Institute of Arthritis and Musculoskeletal and Skin Diseases
(R01-AR068067 to B.A. and R01-AR073172 to W.T.). The
model of CD47 in Figs. 1 and 2 were based off the DNA
sequence from protein data base entry 2JJS and were modeled
using the Chimera Program from the University of California,
San Diego.
References
1. D. B. Nikolov, K. Xu, and J. P. Himanen, “Homotypic receptor-receptor
interactions regulating Eph signaling,” Cell Adhes. Migr. 8(4), 360–365
(2014).
2. E. M. Lisabeth, G. Falivelli, and E. B. Pasquale, “Eph receptor signaling
and ephrins,” Cold Spring Harb. Perspect. Biol. 5(9), a009159 (2013).
Fig. 7 Cellular fluorescence of control and ephrin-B2 hDMVECs incubated with F-NETs at various ρ
values. (a) Fluorescent images of control and ephbin-B2 hDMVECs after 40 min of incubation at 4°C with
F-NETs solutions. All images are falsely colored with the blue and red corresponding to DAPI and ICG
NIR emission from the NETs, respectively. Scale bars are 30 μm. (b) Averaged fluorescence intensity (I)
[see Eq. (3)] as a function of ρ. Cells from 3 to 4 images were analyzed, resulting in 16 to 41 measure-
ments for each combination of nanoparticles and cells. Statistical significance of p < 0.001 is denoted by
***. Only statistically significant populations with the same ρ value of F-NETs are indicated. (c) Sigmoidal
fit to the I values of the ephrin-B2 hDMVECs versus the ρ value of F-NETs. Error bars in (b) and (c) re-
present SDs.
Journal of Biomedical Optics 085002-7 August 2019 • Vol. 24(8)
Hanley et al.: Functionalized erythrocyte-derived optical nanoparticles. . .
3. C. T. Blits-Huizinga et al., “Ephrins and their receptors: binding versus
biology,” IUBMB Life 56(5), 257–265 (2004).
4. E. B. Pasquale, “The Eph family of receptors,” Curr. Opin. Cell Biol.
9(5), 608–615 (1997).
5. Eph Nomenclature Committee, “Unified nomenclature for Eph family
receptors and their ligands, the ephrins,” Cell 90(3), 403–404 (1997).
6. J. Frisén, J. Holmberg, and M. Barbacid, “Ephrins and their Eph recep-
tors: multitalented directors of embryonic development,” EMBO J.
18(19), 5159–5165 (1999).
7. K. Kullander and R. Klein, “Mechanisms and functions of Eph and eph-
rin signalling,” Nat. Rev. Mol. Cell Biol. 3(7), 475–486 (2002).
8. H. Surawska, P. C. Ma, and R. Salgia, “The role of ephrins and Eph
receptors in cancer,” Cytokine Growth Factor Rev. 15(6), 419–433
(2004).
9. C. M. Edwards and G. R. Mundy, “Eph receptors and ephrin signaling
pathways: a role in bone homeostasis,” Int. J. Med. Sci. 5(5), 263–272
(2008).
10. E. B. Pasquale, “Eph-ephrin bidirectional signaling in physiology and
disease,” Cell 133(1), 38–52 (2008).
11. Y. Chen, A. K. Y. Fu, and N. Y. Ip, “Eph receptors at synapses: impli-
cations in neurodegenerative diseases,” Cell. Signalling 24(3), 606–611
(2012).
12. W. Tan et al., “Coexistence of Eph receptor B1 and ephrin B2 in port-
wine stain endothelial progenitor cells contributes to clinicopathological
vasculature dilatation,” Br. J. Dermatol. 177, 1601–1611 (2017).
13. S. J. Riedl and E. B. Pasquale, “Targeting the Eph system with peptides
and peptide conjugates,” Curr. Drug Targets 16(10), 1031–1047 (2015).
14. Z. Wang et al., “Specific photothermal therapy to the tumors with high
EphB4 receptor expression,” Biomaterials 68, 32–41 (2015).
15. K. S. Blevins et al., “EphA2 targeting peptide tethered bioreducible pol-
y(cystamine bisacrylamide–diamino hexane) for the delivery of thera-
peutic pCMV-RAE-1γ to pancreatic islets,” J. Controlled Release
158(1), 115–122 (2012).
16. A. M. Gobin, J. J. Moon, and J. L. West, “EphrinAl-targeted nanoshells
for photothermal ablation of prostate cancer cells,” Int. J. Nanomed.
3(3), 351–358 (2008).
17. J. D. Obayemi et al., “Adhesion of ligand-conjugated biosynthesized
magnetite nanoparticles to triple negative breast cancer cells,”
J. Mech. Behav. Biomed. Mater. 68, 276–286 (2017).
18. K. Zhang et al., “Comprehensive optimization of a single-chain variable
domain antibody fragment as a targeting ligand for a cytotoxic nano-
particle,” MAbs 7(1), 42–52 (2014).
19. A. M. Alkilany et al., “Homing peptide-conjugated gold nanorods: the
effect of amino acid sequence display on nanorod uptake and cellular
proliferation,” Bioconjug. Chem. 25(6), 1162–1171 (2014).
20. A. Barquilla and E. B. Pasquale, “Eph receptors and ephrins: therapeutic
opportunities,” Annu. Rev. Pharmacol. Toxicol. 55, 465–487 (2015).
21. C.-M. J. Hu et al., “Erythrocyte membrane-camouflaged polymeric
nanoparticles as a biomimetic delivery platform,” Proc. Natl. Acad.
Sci. U. S. A. 108(27), 10980–10985 (2011).
22. B. Bahmani, D. Bacon, and B. Anvari, “Erythrocyte-derived photo-
theranostic agents: hybrid nano-vesicles containing indocyanine green
for near infrared imaging and therapeutic applications,” Sci. Rep. 3,
2180 (2013).
23. J. T. Mac et al., “Erythrocyte-derived nano-probes functionalized with
antibodies for targeted near infrared fluorescence imaging of cancer
cells,” Biomed. Opt. Express 7(4), 1311–1322 (2016).
24. R. Vankayala et al., “Erythrocyte-derived nanoparticles as a theranostic
agent for near-infrared fluorescence imaging and thrombolysis of blood
clots,” Macromol. Biosci. 18, e1700379 (2018).
25. Y. Guo et al., “Erythrocyte membrane-enveloped polymeric nanopar-
ticles as nanovaccine for induction of antitumor immunity against mela-
noma,” ACS Nano 9(7), 6918–6933 (2015).
26. R. H. Fang, C.-M. J. Hu, and L. Zhang, “Nanoparticles disguised as red
blood cells to evade the immune system,” Expert Opin. Biol. Ther.
12(4), 385–389 (2012).
27. R. Li et al., “Cell membrane-based nanoparticles: a new biomimetic
platform for tumor diagnosis and treatment,” Acta Pharm. Sin. B
8(1), 14–22 (2018).
28. J.-M. Liu et al., “Erythrocyte membrane bioinspired near-infrared per-
sistent luminescence nanocarriers for in vivo long-circulating bioimag-
ing and drug delivery,” Biomaterials 165, 39–47 (2018).
29. X.Wan et al., “Red blood cell-derived nanovesicles for safe and efficient
macrophage-targeted drug delivery in vivo,” Biomater. Sci. 7, 187–195
(2018).
30. Q. Zhang et al., “Neutrophil membrane-coated nanoparticles inhibit
synovial inflammation and alleviate joint damage in inflammatory
arthritis,” Nat. Nanotechnol. 13(12), 1182–1190 (2018).
31. J. Li et al., “Cell membrane coated semiconducting polymer nanopar-
ticles for enhanced multimodal cancer phototheranostics,” ACS Nano
12(8), 8520–8530 (2018).
32. C.-M. J. Hu, R. H. Fang, and L. Zhang, “Erythrocyte-inspired delivery
systems,” Adv. Healthc. Mater. 1(5), 537–547 (2012).
33. J.-W. Yoo et al., “Bio-inspired, bioengineered and biomimetic drug
delivery carriers,” Nat. Rev. Drug Discov. 10(7), 521–535 (2011).
34. A. A. Bentley and J. C. Adams, “The evolution of thrombospondins and
their ligand-binding activities,” Mol. Biol. Evol. 27(9), 2187–2197
(2010).
35. P. A. Oldenborg et al., “Role of CD47 as a marker of self on red blood
cells,” Science 288(5473), 2051–2054 (2000).
36. P.-A. Oldenborg, “CD47: a cell surface glycoprotein which regulates
multiple functions of hematopoietic cells in health and disease,”
ISRN Hematol. 2013, 1–19 (2013).
37. P. L. Rodriguez et al., “Minimal ‘self’ peptides that inhibit phagocytic
clearance and enhance delivery of nanoparticles,” Science 339(6122),
971–975 (2013).
38. H. Zhang, “Erythrocytes in nanomedicine: an optimal blend of
natural and synthetic materials,” Biomater. Sci. 4(7), 1024–1031
(2016).
39. J. M. Burns et al., “Erythrocyte-derived theranostic nanoplatforms for
near infrared fluorescence imaging and photodestruction of tumors,”
ACS Appl. Mater. Interfaces 10(33), 27621–27630 (2018).
40. C. Minelli and A. G. Shard, “Chemical measurements of polyethylene
glycol shells on gold nanoparticles in the presence of aggregation,”
Biointerphases 11(4), 04B306 (2016).
41. J. M. Burns et al., “Optical properties of biomimetic probes engineered
from erythrocytes,” Nanotechnology 28(3), 035101 (2017).
42. J. C. Tang, A. Partono, and B. Anvari, “Near-infrared-fluorescent eryth-
rocyte-mimicking particles: physical and optical characteristics,” IEEE
Trans. Biomed. Eng. 66(4), 1034–1044 (2018).
43. J. E. Noble and M. J. A. Bailey, “Quantitation of protein,” inMethods in
Enzymology, R. R. Burgess and M. P. Deutscher, Eds., Vol. 463, pp. 73–
95, Academic Press, Amsterdam (2009).
44. N. Baumgarth and M. Roederer, “A practical approach to multicolor
flow cytometry for immunophenotyping,” J. Immunol. Methods 243(1),
77–97 (2000).
45. D. A. Bryant, “Phycoerythrocyanin and phycoerythrin: properties
and occurrence in cyanobacteria,” Microbiology 128(4), 835–844
(1982).
46. S. Behzadi et al., “Cellular uptake of nanoparticles: journey inside the
cell,” Chem. Soc. Rev. 46(14), 4218–4244 (2017).
47. J. K. Chen et al., “An overview of clinical and experimental treatment
modalities for port wine stains,” J. Am. Acad. Dermatol. 67(2), 289–
304.e29 (2012).
48. S. L. Jacques, “Optical properties of biological tissues: a review,” Phys.
Med. Biol. 58(11), R37 (2013).
49. J. Burns et al., “Photothermal treatment of port-wine stains using eryth-
rocyte-derived particles doped with indocyanine green: a theoretical
study,” J. Biomed. Opt. 23, 121616 (2018).
Taylor Hanley is a PhD candidate in bioengineering at the University
of California, Riverside, California, USA. She received her MS degree
in bioengineering from the University of California, Riverside,
California, and her BS degree in biochemistry from Harvey Mudd
College, Claremont, California. Her research focuses on functionaliz-
ing erythrocyte-derived nanoparticles to target specific diseased cell
states for their imaging or phototherapy, as well as investigating the
immunogenicity of these nanoparticles.
Rong Yin is a postdoctoral fellow in the Department of Cell Biology
and Anatomy at the University of South Carolina School of Medicine.
She holds her PhD in dermatological science from the Forth Military
Medical University, China, 2018. Her research interests include the
development of novel nanoparticles for photodynamic therapy for
patients with congenital vascular malformations.
Journal of Biomedical Optics 085002-8 August 2019 • Vol. 24(8)
Hanley et al.: Functionalized erythrocyte-derived optical nanoparticles. . .
Jenny T. Mac is a PhD candidate in biochemistry and molecular biol-
ogy at the University of California, Riverside, California. She received
her MS degree in biochemistry and molecular biology and BS degree
in biochemistry from the University of California, Riverside, California.
Her research focuses on erythrocyte-derived delivery systems for
fluorescent imaging and phototherapeutics of cancer cells, as well
as investigating the biodistribution of these particles.
Wenbin Tan is an associate professor at the University of South
Carolina School of Medicine. He holds a PhD in neurobiology and
neurophysiology from the University of California, Los Angeles,
in 2008. His current research interests include the molecular patho-
genesis of congenital vascular malformations and development of
new treatments for these diseases.
Bahman Anvari is a professor in the Department of Bioengineering
at University of California, Riverside. His research interests are in
photomedicine with current focus on the engineering of delivery plat-
forms for light-based theranostics. He is a fellow of the American
Association for the Advancement of Science (AAAS), the American
Institute for Medical and Biological Engineering (AIMBE), the
Biomedical Engineering Society (BMES), and SPIE.
Journal of Biomedical Optics 085002-9 August 2019 • Vol. 24(8)
Hanley et al.: Functionalized erythrocyte-derived optical nanoparticles. . .
